Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 1/20 | 0.64 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.64 |
| ▸ | PIM1 | P11309 | 6/20 | 0.54 |
| ▸ | PIM3 | Q86V86 | 6/20 | 0.54 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.53 |
| ▸ | TDO2 | P48775 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27868506 | 0.91 | TRIM24 (0.54) | TRIM24TRIM33PIM1PIM3PIM2 | |
| SCHEMBL29954763 | 0.82 | TRIM24 (0.70) | TRIM24TRIM33PIM1PIM3PIM2 | |
| SCHEMBL29955386 | 0.79 | TRIM24 (0.66) | TRIM24TRIM33PIM1PIM3PIM2 | |
| SCHEMBL27640740 | 0.79 | TDO2 (0.50) | TRIM24TRIM33PIM1PIM3TDO2 | |
| SCHEMBL16067373 | 0.78 | PIM3 (0.77) | TRIM24TRIM33PIM1PIM3PIM2 | |
| SCHEMBL17829692 | 0.78 | CSNK2A2 (0.50) | TRIM24TRIM33PIM1PIM3PIM2 | |
| SCHEMBL29954012 | 0.78 | TRIM24 (0.64) | TRIM24TRIM33PIM1PIM3PIM2 | |
| SCHEMBL29953184 | 0.78 | PIM3 (0.77) | TRIM24TRIM33PIM1PIM3PIM2 | |
| SCHEMBL672635 | 0.78 | TRIM24 (1.00) | TRIM24TRIM33PIM1PIM3PIM2 | |
| SCHEMBL1092989 | 0.78 | TRIM24 (0.64) | TRIM24TRIM33PIM1PIM3PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102584670-B | Indole-3-formaldehyde shrinkage phenylenediamine bis-schiff base and preparation method thereof | SHANDONG INST LIGHT INDUSTRY | 2014-04-02 | — | — | CN | claimed |
| CN-102584796-B | Bis-Schiff bases synthesized by condensing indole-3-carboxaldehyde and pyridine diamine and preparation method thereof | SHANDONG INST LIGHT INDUSTRY | 2013-12-11 | — | — | CN | claimed |
| CN-102584671-B | Bis-Schiff bases synthesized by condensing indole-3-carboxaldehyde and benzidine and preparation method thereof | SHANDONG INST LIGHT INDUSTRY | 2013-08-07 | — | — | CN | claimed |
| CN-102584796-A | Bis-Schiff bases synthesized by condensing indole-3-carboxaldehyde and pyridine diamine and preparation method thereof | SHANDONG INST LIGHT INDUSTRY | 2012-07-18 | — | — | CN | claimed |
| CN-102584671-A | Bis-Schiff bases synthesized by condensing indole-3-carboxaldehyde and benzidine and preparation method thereof | SHANDONG INST LIGHT INDUSTRY | 2012-07-18 | — | — | CN | claimed |
| CN-102584670-A | Indole-3-formaldehyde shrinkage phenylenediamine bis-schiff base and preparation method thereof | SHANDONG INST LIGHT INDUSTRY | 2012-07-18 | — | — | CN | claimed |
| US-20250177538-A1 | Methods for synthesizing deuterated formylindoles | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2025-06-05 | — | — | US | disclosed |
| US-12012411-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2024-06-18 | — | — | US | disclosed |
| WO-2023250348-A2 | METHODS FOR SYNTHESIZING DEUTERATED FORMYLINDOLES | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023183394-A1 | ALPHA 1A-ADRENERGIC RECEPTOR AGONISTS AND METHODS OF USE | CURASEN THERAPEUTICS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-04-07 | — | — | US | disclosed |
| US-11279704-B2 | Viral replication inhibitors | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2022-03-22 | — | — | US | disclosed |
| EP-1560584-A4 | FAB I INHIBITORS | AFFINIUM PHARM INC (CA) | 2005-10-12 | — | — | EP | disclosed |
| EP-1560584-A2 | FAB I INHIBITORS | Affinium Pharmaceuticals, Inc. (CA) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004082586-A2 | PHAMACEUTICAL COMPOSITIONS COMPRISING INHIBITORS OF FAB I AND FURTHER ANTIBIOTICS | AFFINIUM PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040147580-A1 | Fab I inhibitors | DEBIOPHARM INTERNATIONAL SA (CH) | 2004-07-29 | — | — | US | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003088897-A2 | FAB I INHIBITORS | AFFINIUM PHARMACEUTICALS, INC. (CA) | 2003-10-30 | — | — | WO | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177538-A1 | Methods for synthesizing deuterated formylindoles | TDO2, CISD2, ALAD | TRIM24 3946/4885TRIM33 2641/4885PIM1 4839/4885 |
| US-11279704-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | TRIM24 462/4885TRIM33 448/4885PIM1 1237/4885 |
| US-20040147580-A1 | Fab I inhibitors | SERPINB1, TMBIM6, GDI1 | TRIM24 3167/4885TRIM33 3809/4885PIM1 113/4885 |
| US-20220106321-A1 | VIRAL REPLICATION INHIBITORS | EIF2AK2, MAVS, ZC3HAV1 | TRIM24 462/4885TRIM33 448/4885PIM1 1237/4885 |
| US-12012411-B2 | Viral replication inhibitors | EIF2AK2, MAVS, ZC3HAV1 | TRIM24 462/4885TRIM33 448/4885PIM1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.